Wells Fargo’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-12,783
| Closed | -$1.3M | – | 7728 |
|
|
2023
Q2 | $1.3M | Buy |
12,783
+5,867
| +85% | +$555K | ﹤0.01% | 3257 |
|
|
2023
Q1 | $629K | Buy |
6,916
+6,054
| +702% | +$355K | ﹤0.01% | 3695 |
|
|
2022
Q4 | $32.7K | Sell |
862
-133
| -13% | -$4.58K | ﹤0.01% | 5050 |
|
|
2022
Q3 | $25K | Sell |
995
-1,131
| -53% | -$31.3K | ﹤0.01% | 5298 |
|
|
2022
Q2 | $65K | Sell |
2,126
-7,956
| -79% | -$237K | ﹤0.01% | 4900 |
|
|
2022
Q1 | $330K | Sell |
10,082
-17,763
| -64% | -$527K | ﹤0.01% | 4697 |
|
|
2021
Q4 | $734K | Buy |
27,845
+8,826
| +46% | +$683K | ﹤0.01% | 4368 |
|
|
2021
Q3 | $1.91M | Buy |
19,019
+4,081
| +27% | +$478K | ﹤0.01% | 3705 |
|
|
2021
Q2 | $2.11M | Buy |
14,938
+4,796
| +47% | +$542K | ﹤0.01% | 3646 |
|
|
2021
Q1 | $1.01M | Sell |
10,142
-357
| -3% | -$41.6K | ﹤0.01% | 4241 |
|
|
2020
Q4 | $1.3M | Sell |
10,499
-2,451
| -19% | -$322K | ﹤0.01% | 3824 |
|
|
2020
Q3 | $1.26M | Buy |
12,950
+4,998
| +63% | +$624K | ﹤0.01% | 3679 |
|
|
2020
Q2 | $1.24M | Sell |
7,952
-7,512
| -49% | -$1.14M | ﹤0.01% | 3644 |
|
|
2020
Q1 | $2.23M | Sell |
15,464
-2,456
| -14% | -$474K | ﹤0.01% | 2899 |
|
|
2019
Q4 | $3.66M | Sell |
17,920
-67,873
| -79% | -$12.4M | ﹤0.01% | 2842 |
|
|
2019
Q3 | $6.89M | Buy |
85,793
+49,325
| +135% | +$4.19M | ﹤0.01% | 2262 |
|
|
2019
Q2 | $3.44M | Sell |
36,468
-6,939
| -16% | -$599K | ﹤0.01% | 2888 |
|
|
2019
Q1 | $3.71M | Sell |
43,407
-1,899
| -4% | -$158K | ﹤0.01% | 2825 |
|
|
2018
Q4 | $2.54M | Buy |
45,306
+22,041
| +95% | +$1.35M | ﹤0.01% | 3070 |
|
|
2018
Q3 | $1.9M | Buy |
23,265
+666
| +3% | +$46.9K | ﹤0.01% | 3453 |
|
|
2018
Q2 | $790K | Buy |
22,599
+1,908
| +9% | +$58.1K | ﹤0.01% | 4158 |
|
|
2018
Q1 | $425K | Sell |
20,691
-25,776
| -55% | -$663K | ﹤0.01% | 4515 |
|
|
2017
Q4 | $1.32M | Buy |
46,467
+11,095
| +31% | +$310K | ﹤0.01% | 3724 |
|
|
2017
Q3 | $1.1M | Buy |
35,372
+29,781
| +533% | +$896K | ﹤0.01% | 3775 |
|
|
2017
Q2 | $176K | Buy |
5,591
+1,521
| +37% | +$37.4K | ﹤0.01% | 4860 |
|
|
2017
Q1 | $93K | Hold |
4,070
| – | – | ﹤0.01% | 5230 |
|
|
2016
Q4 | $88K | Buy |
4,070
+1,913
| +89% | +$48.4K | ﹤0.01% | 5215 |
|
|
2016
Q3 | $57K | Buy |
+2,157
| New | +$42.8K | ﹤0.01% | 5236 |
|
Other funds holding RETA
Wells Fargo's RETA Position: Q3 2023 in Review
Wells Fargo sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 12,783 shares — an estimated $1.3M sold.
Wells Fargo first reported a position in RETA in Q3 2016 and held it in 28 quarters. The position peaked at $6.89M in Q3 2019. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Wells Fargo reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Wells Fargo sold 12,783 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $1.3M.
- Wells Fargo first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2016 and held it in 28 quarters.
- Wells Fargo's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $6.89M in Q3 2019.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Wells Fargo's 13F filing for Q3 2023, filed 13 Nov 2023.